- Home
- KOD vs ATYR Comparison
KOD vs ATYR Comparison
Compare KOD & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- ATYR
- Stock Information
- Founded
- KOD 2009
- ATYR 2005
- Country
- KOD United States
- ATYR United States
- Employees
- KOD N/A
- ATYR N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KOD Health Care
- ATYR Health Care
- Exchange
- KOD Nasdaq
- ATYR Nasdaq
- Market Cap
- KOD 186.3M
- ATYR 228.1M
- IPO Year
- KOD 2018
- ATYR 2015
- Fundamental
- Price
- KOD $8.72
- ATYR $3.30
- Analyst Decision
- KOD Hold
- ATYR Strong Buy
- Analyst Count
- KOD 5
- ATYR 4
- Target Price
- KOD $6.80
- ATYR $19.25
- AVG Volume (30 Days)
- KOD 473.7K
- ATYR 787.2K
- Earning Date
- KOD 11-14-2024
- ATYR 11-07-2024
- Dividend Yield
- KOD N/A
- ATYR N/A
- EPS Growth
- KOD N/A
- ATYR N/A
- EPS
- KOD N/A
- ATYR N/A
- Revenue
- KOD N/A
- ATYR $235,000.00
- Revenue This Year
- KOD N/A
- ATYR N/A
- Revenue Next Year
- KOD N/A
- ATYR $1,200.54
- P/E Ratio
- KOD N/A
- ATYR N/A
- Revenue Growth
- KOD N/A
- ATYR N/A
- 52 Week Low
- KOD $2.19
- ATYR $1.34
- 52 Week High
- KOD $11.60
- ATYR $3.80
- Technical
- Relative Strength Index (RSI)
- KOD 64.72
- ATYR 52.43
- Support Level
- KOD $8.03
- ATYR $3.05
- Resistance Level
- KOD $9.55
- ATYR $3.26
- Average True Range (ATR)
- KOD 0.89
- ATYR 0.22
- MACD
- KOD -0.08
- ATYR -0.03
- Stochastic Oscillator
- KOD 36.51
- ATYR 30.00
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.